CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
[14C]-lasmiditandrug
Likely dose
[14C]-lasmiditan 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03040362
NCT03040362Phase 1Completed
CompareCT.gov

A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Lasmiditan Following Single Oral Dose Administration in Healthy Male and Female Subjects

Eli Lilly and Company·interventional·Posted Feb 2, 2017·Updated Jan 10, 2020

In Brief

A Phase 1 clinical trial evaluating [14C]-lasmiditan for Healthy. Completed, enrolled 8 participants across 1 site.

Detailed Summary

This study will be an open-label, nonrandomized, absorption, metabolism, and excretion study of \[14C\]-lasmiditan administered as a 200-milligrams (mg) (approximately 100 microcuries\[µCi\]) oral solution to 8 healthy males and females, following at least a 10 hour fast from food to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of a single oral dose of 200 mg (approximately 100 µCi) \[14C\] lasmiditan in healthy males and females.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
CollaboratorsCoLucid Pharmaceuticals

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2, 2017
Enrollment StartApr 20, 2017
Primary CompletionMay 6, 2017
TodayJul 2, 2026
Enrollment to primary: 16 daysPosted 9.4 years ago

Interventions

[14C]-lasmiditandrug

\[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution